- Home
- NIU vs FHTX Comparison
NIU vs FHTX Comparison
Compare NIU & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIU
- FHTX
- Stock Information
- Founded
- NIU 2014
- FHTX 2015
- Country
- NIU China
- FHTX United States
- Employees
- NIU N/A
- FHTX N/A
- Industry
- NIU Auto Manufacturing
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- NIU Consumer Discretionary
- FHTX Health Care
- Exchange
- NIU Nasdaq
- FHTX Nasdaq
- Market Cap
- NIU 275.6M
- FHTX 278.1M
- IPO Year
- NIU 2018
- FHTX 2020
- Fundamental
- Price
- NIU $4.99
- FHTX $4.98
- Analyst Decision
- NIU
- FHTX Strong Buy
- Analyst Count
- NIU 0
- FHTX 8
- Target Price
- NIU N/A
- FHTX $12.63
- AVG Volume (30 Days)
- NIU 873.5K
- FHTX 106.1K
- Earning Date
- NIU 08-11-2025
- FHTX 08-05-2025
- Dividend Yield
- NIU N/A
- FHTX N/A
- EPS Growth
- NIU N/A
- FHTX N/A
- EPS
- NIU N/A
- FHTX N/A
- Revenue
- NIU $527,760,629.00
- FHTX $24,173,000.00
- Revenue This Year
- NIU $41.32
- FHTX $33.60
- Revenue Next Year
- NIU $24.38
- FHTX $5.87
- P/E Ratio
- NIU N/A
- FHTX N/A
- Revenue Growth
- NIU 32.62
- FHTX N/A
- 52 Week Low
- NIU $1.66
- FHTX $2.95
- 52 Week High
- NIU $5.37
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- NIU 79.79
- FHTX 44.97
- Support Level
- NIU $3.41
- FHTX $4.48
- Resistance Level
- NIU $4.57
- FHTX $5.23
- Average True Range (ATR)
- NIU 0.30
- FHTX 0.39
- MACD
- NIU 0.15
- FHTX -0.07
- Stochastic Oscillator
- NIU 80.61
- FHTX 23.65
About NIU Niu Technologies
Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, mopeds and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.